Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy

Journal of Clinical Oncology

Volumn 16, Issue 9, 1998, Pages 3179-3190

  Phillips, Kelly Anne ^a   Tannock, Ian F ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ERYTHROPOIETIN; ETOPOSIDE; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; MITOXANTRONE; PREDNISONE; PROTECTIVE AGENT; RAZOXANE; VINCRISTINE;

BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CARDIOTOXICITY; DRUG SCREENING; DRUG TOXICITY; HEART PROTECTION; METHODOLOGY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; THROMBOCYTOPENIA;

EID: 0031698016     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.9.3179     Document Type: Review

References (87)

1. DeMulder PHM, Seynaeve C, Vermorken JB, et al: Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann Intern Med 113:834-840, 1990
2. Roila F, Tonato M, Cognetti F, et al: Prevention of cisplatin-induced emesis: A double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 9:675-678, 1991
3. Kris MG, Gralla RJ, Clark RA, et al: Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin. J Natl Cancer Inst 81:42-46, 1989
4. Grunberg SM, Lane M, Lester EP, et al: Randomized double-blind comparison of three dose levels of intravenous ondansetron in the prevention of cisplatin-induced emesis. Cancer Chemother Pharmacol 32:268-272, 1993
5. Osoba D, Warr DG, Fitch MI, et al: Guidelines for the optimal management of chemotherapy-induced nausea and vomiting: A consensus. Can J Oncol 5:381-400, 1995
6. Von Hoff DD, Layard M, Basa P, et al: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717, 1979
7. Nielsen D, Jensen JB, Dombernowsky P, et al: Epirubicin cardiotoxicity: A study of 135 patients with advanced breast cancer. J Clin Oncol 8:1806-1810, 1990
8. Lefrak EA, Pitha J, Rosenheim S, et al: A clinicopathologic analysis of Adriamycin cardiotoxicity. Cancer 32:302-314, 1973
9. Minow RA, Benjamin RA, Gottleib JA: Adriamycin (NSC-123127) cardiomyopathy - An overview with determination of risk factors. Cancer Chemother Rep 6:195-201, 1975
10. Wong KY, Lampkin BC: Anthracycline toxicity. Am J Pediatr Hematol Oncol 5:93-97, 1983
11. Sallen SE, Clavell LA: Cardiac effects of anthracyclines used in the treatment of childhood acute lymphoblastic leukemia: A 10 year experience. Semin Oncol 11:19-21, 1984 (suppl 3)
12. Myers CE, McGuire WP, Liss RH, et al: Adriamycin: The role of lipid peroxidation in cardiac toxicity and tumor response. Science 197:165-167, 1977
13. Sobol MM, Amiet RG, Green MD: In vitro evidence for direct complexation of ADR-529/ICRF-187 [(+)-1,2bis-(3,5-dioxopiperazinyl-1-yl)propane] onto an existing ferric-anthracycline complex. Mol Pharmacol 41:8-16, 1991
14. Hasinoff BB: The interaction of the cardioprotective agent ICRF-187 ((+)-1,2bis-(3,5-dioxopiperazinyl-1-yl)propane); Its hydrolysis product (ICRF-198) and other chelating agents with the Fe(III) and Cu(II) complexes of Adriamycin. Agents Act 26:378-385, 1989
15. Speyer JL, Green MD, Kramer E, et al: Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 319:745-752, 1988
16. Speyer JL, Green MD, Sanger J, et al: A prospective randomized trial of ICRF-187 for prevention of cumulative doxorubicin-induced cardiac toxicity in women with breast cancer. Cancer Treat Rev 17:161-163, 1990
17. Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al: ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 10:117-127, 1992
18. Venturini M, Michelotti A, Del Mastro L, et al: Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol 14:3112-3120, 1996
19. Wexler LH, Andrich MP, Venzon D, et al: Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 14:362-372, 1996
20. Swain SM, Whaley FS, Gerber MC, et al: Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 15:1333-1340, 1997
21. Swain SM, Whaley FS, Gerber MC, et al: Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15:1318-1332, 1997
22. Lopez M, Vici P, Di Lauro L, et al: Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. J Clin Oncol 16:86-92, 1998
23. Chlebowski RT, Lillington LM: A decade of breast cancer clinical investigation: Results as reported in the Program/Proceedings of the American Society of Clinical Oncology. J Clin Oncol 12:1789-1795, 1994
24. Groopman JE, Molina JM, Scadden DT: Hematopoietic growth factors: Biology and clinical applications. N Engl J Med 321:1449-1459, 1989
25. Metcalf D, Morstyn G: Colony-stimulating factors: General biology, in DeVita VT, Hellman S, Rosenberg SA (eds): Biologic Therapy of Cancer. Philadelphia, PA, Lippincott, 1991, pp 417-444
26. Azuma J, Kurimoto T, Awata S, et al: Phase I study of KRN8601 (rhG-CSF) in normal healthy volunteers: Safety and pharmacokinetics in single subcutaneous administration. Rinsho Iyaku 5:2231-2252, 1989
27. Bronchud MH, Scarffe JH, Thatcher N, et al: Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 56:809-813, 1987
28. Antman KS, Griffin JD, Elias E, et al: Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med 319:593-598, 1988
29. Gabrilove JL, Jakubowski A, Scher H, et al: Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318:1414-1422, 1988
30. Brandt SJ, Peters WP, Atwater SK, et al: Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 318:869-876, 1988
31. Ohno R, Tomonaga M, Kobayashi T, et al: Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 323:871-877, 1990
32. Ohno R, Naoe T, Kanamura A, et al: A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Blood 83:2086-2092, 1994
33. Godwin J: Design and conduct of a double-blind, placebo-controlled trial of daunorubicin and cytarabine with or without granulocyte colony-stimulating factor in elderly patients with acute myeloid leukemia: A Southwest Oncology Group study. J Natl Cancer Inst 19:31-35, 1995
34. Rowe JM, Anderson JW, Mazza JJ, et al: A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group. Blood 86:457-462, 1995
35. Dombret H, Chastang C, Fenaux P, et al: A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med 332:1678-1683, 1995
36. Stone RM, Berg DT, George SL, et al: Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 332:1671-1677, 1995
37. Heil G, Chadid L, Hoezler D, et al: GM-CSF in a double-blind randomized, placebo controlled trial in therapy of adult patients with de novo acute myeloid leukemia (AML). Leukemia 9:3-9, 1995
38. Zittoun R, Suciu S, Mandelli F, et al: Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: A randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol 14:2150-2159, 1996
39. Heil G, Hoelzer D, Sanz MA, et al: A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. Blood 90:4710-4718, 1997
40. Geissler K, Koller K, Hubman E, et al: Granulocyte colony-stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia - A randomized phase-III study. Blood 90:590-596, 1997
41. ASCO: Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based clinical practice guidelines. J Clin Oncol 14:1957-1960, 1996
42. Crawford J, Ozer H, Stoller R, et al: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164-170, 1991
43. Pettengell R, Gurney H, Radford JA, et al: Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized controlled trial. Blood 80:1430-1436, 1992
44. Kaku K, Takahashi M, Moriyama Y, et al: Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) after chemotherapy in patients with non-Hodgkin's lymphoma: A placebo-controlled double blind phase III trial. Leuk Lymphoma 11:229-238, 1993
45. Gerhartz HH, Engelhard M, Meusers P, et al: Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas. Blood 82:2329-2339, 1993
46. Ardizzoni A, Venturini M, Sertoli MR, et al: Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: A randomized study in patients with advanced breast cancer. Br J Cancer 69:385-391, 1994
47. Bunn PA, Crowley J, Kelly K, et al: Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: A prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol 13:1632-1641, 1995
48. Chevallier B, Chollet P, Merrouche Y, et al: Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol 13:1564-1571, 1995
49. Jones SE, Schottstaedt MW, Duncan LA, et al: Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer. J Clin Oncol 14:2976-2983, 1996
50. Gisselbrecht C, Haioun C, Lepage E, et al: Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: Factors influencing chemotherapy administration. Leuk Lymphoma 25:289-300, 1997
51. Negoro S, Masuda N, Furuse K, et al: Dose-intense chemotherapy in extensive-stage small-cell lung cancer. Cancer Chemother Pharmacol 40:S70-73, 1997 (suppl)
52. Johnson DH, Einhorn LH, Birch R, et al: A randomized comparison of high dose versus conventional dose cyclophosphamide, doxorubicin and vincristine for extensive stage small cell lung cancer: A phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 5:1731-1738, 1987
53. Einhorn L: Initial therapy with cisplatin plus VP-16 in small cell lung cancer. Semin Oncol 13:5-9, 1986
54. Nichols CR, Fox EP, Roth BJ, et al: Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor. J Clin Oncol 12:1245-1250, 1994
55. Vanchieri C: Persistent high hopes held for colony stimulating factors. J Natl Cancer Inst 85:1982-1983, 1993
56. Vanchieri C: Biotech industry flourishes with cancer research advances. J Natl Cancer Inst 83:1608-1611, 1991
57. Engelhard M, Meusers P, Brittinger G, et al: Prospective multicenter trial for the response-adapted treatment of high-grade malignant non-Hodgkin's lymphomas: Updated results of the COP-BLAM/IMVP-16 protocol with randomized adjuvant radiotherapy. Ann Oncol 2:177-180, 1992
58. Fisher RI, Gaaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006, 1993
59. Fisher RI: Treatment of aggressive non-Hodgkin's lymphomas: Lessons from the past 10 years. Cancer 74:2657-2661, 1994
60. Savarese DMF, Hsieh CC, Stewart FM: Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors. J Clin Oncol 15:2891-2895, 1997
61. Siu LL, Tannock IF: Chemotherapy dose escalation: Case unproven. J Clin Oncol 15:2765-2768, 1997 (editorial)
62. Gamucci T, Thorel MF, Frasca AM, et al: Erythropoietin for the prevention of anemia in neoplastic patients treated with cisplatin. Eur J Cancer 29A:S13-S14, 1993 (suppl 2)
63. Abels R: Erythropoietin for anemia in cancer patients. Eur J Cancer 29A:S2-S8, 1993 (suppl 2)
64. Case DC, Bukowski RM, Carey RW, et al: Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 85:801-806, 1993
65. Cascinu S, Fedeli A, Del Ferro E, et al: Recombinant human erythropoietin treatment in cisplatin-associated anemia: A randomized, double-blind trial with placebo. J Clin Oncol 12:1058-1062, 1994
66. Del Mastro L, Venturini M, Lionetto R, et al: Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol 15:2715-2721, 1997
67. Bartley TD, Bogenberger J, Hunt P, et al: Identification and cloning of a megacaryocyte growth and development factor that is a ligand for the cytokine receptor mpl. Cell 77:1117-1124, 1994
68. Kaushansky K, Lok S, Holly RD, et al: Promotion of a megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 369:568-571, 1994
69. Zeigler FC, deSauvage F, Widmer HR, et al: In vitro megakaryocytopoietic and thrombopoietic activity of c-mpl ligand (TPO) on purified murine hematopoietic stem cells. Blood 84:4045-4052, 1994
70. Kaushansky K, Broudy VC, Lin N, et al: Thrombopoietin, the Mpl-ligand, is essential for full megakaryocyte development. Proc Natl Acad Sci USA 92:3234, 1995 (abstr)
71. Hokom MM, Lacey D, Kinstler OB, et al: Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice. Blood 86:4486-4492, 1995
72. Fanucci M, Glaspy J, Crawford J, et al: Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 336:404-409, 1997
73. Teramura M, Kobayashi S, Hoshino S, et al: Interleukin-11 enhances human megakaryocytopoiesis in vitro. Blood 79:327-331, 1992
74. Isaacs C, Robert NJ, Bailey A, et al: Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol 15:3368-3377, 1997
75. Capezzi RL. Amifostine: The preclinical basis for broadspectrum selective cytoprotection of normal tissues from cytotoxic therapies. Semin Oncol 23:2-17, 1996 (suppl 6)
76. DeNeve WJ, Everett CK, Suminski JE, et al: Influence of WR-2721 on DNA cross-linking by nitrogen mustard in normal mouse bone marrow and leukemia cells in vivo. Cancer Res 48:6002-6005, 1988
77. Treskes M, Nijtmans LG, Schepman AMJ, et al: Effects of the modulating agent WR2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulphate and diethylthiocarbamate. Biochem Pharmacol 43:1013-1019, 1992
78. Yang YL, Fernandes DJ, Speicher L, et al: Biochemical determinants of the cytoprotective effect of amifostine. Proc Am Assoc Cancer Res 36:290, 1995 (abstr 1725)
79. Calabro-Jones PM, Aguilera JA, Ward JF, et al: Uptake of the WR-2721 derivatives by cells in culture: Identification of the transported form of the drug. Cancer Res 48:3634-3640, 1988
80. Kemp G, Rose P, Lurain J, et al: Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14:2101-2112, 1996
81. McGuire WP, Hoskins WJ, Brady MF, et al: An assessment of dose intense therapy in suboptimally debulked ovarian cancer: A Gynaecologic Oncology Group study. J Clin Oncol 13:1589-1599, 1995
82. Kaye SB, Cassidy JPJ, Lewis CR, et al: Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. J Clin Oncol 14:2113-2119, 1996
83. Poplin EA, LoRusso P, Lokich JJ, et al: Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer. Cancer Chemother Pharmacol 33:415-419, 1994
84. Mercer V, Anderson H, Habboubi N, et al: A phase III randomized study of carboplatin and amifostine versus carboplatin and G-CSF in patients with inoperable non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 16:474a, 1997 (abstr 1708)
85. Daugherty C, Ratain MJ, Grochowski E. et al: Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol 13:1062-1072, 1995
86. Schwartz D, Lellouch J: Explanatory and pragmatic attitudes in therapeutic trials. J Chronic Dis 20:637-648, 1967
87. Fleming T, DeMets DL: Surrogate endpoints in clinical trials: Are we being misled? Ann Intern Med 125:605-613, 1996